Literature DB >> 23225669

Integration-free induced pluripotent stem cells model genetic and neural developmental features of down syndrome etiology.

James A Briggs1, Jane Sun, Jill Shepherd, Dmitry A Ovchinnikov, Tung-Liang Chung, Sam P Nayler, Li-Pin Kao, Carl A Morrow, Nilay Y Thakar, Set-Yen Soo, Teija Peura, Sean Grimmond, Ernst J Wolvetang.   

Abstract

Down syndrome (DS) is the most frequent cause of human congenital mental retardation. Cognitive deficits in DS result from perturbations of normal cellular processes both during development and in adult tissues, but the mechanisms underlying DS etiology remain poorly understood. To assess the ability of induced pluripotent stem cells (iPSCs) to model DS phenotypes, as a prototypical complex human disease, we generated bona fide DS and wild-type (WT) nonviral iPSCs by episomal reprogramming. DS iPSCs selectively overexpressed chromosome 21 genes, consistent with gene dosage, which was associated with deregulation of thousands of genes throughout the genome. DS and WT iPSCs were neurally converted at >95% efficiency and had remarkably similar lineage potency, differentiation kinetics, proliferation, and axon extension at early time points. However, at later time points DS cultures showed a twofold bias toward glial lineages. Moreover, DS neural cultures were up to two times more sensitive to oxidative stress-induced apoptosis, and this could be prevented by the antioxidant N-acetylcysteine. Our results reveal a striking complexity in the genetic alterations caused by trisomy 21 that are likely to underlie DS developmental phenotypes, and indicate a central role for defective early glial development in establishing developmental defects in DS brains. Furthermore, oxidative stress sensitivity is likely to contribute to the accelerated neurodegeneration seen in DS, and we provide proof of concept for screening corrective therapeutics using DS iPSCs and their derivatives. Nonviral DS iPSCs can therefore model features of complex human disease in vitro and provide a renewable and ethically unencumbered discovery platform.
Copyright © 2012 AlphaMed Press.

Entities:  

Mesh:

Year:  2013        PMID: 23225669     DOI: 10.1002/stem.1297

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  70 in total

1.  DYRK1A overexpression enhances STAT activity and astrogliogenesis in a Down syndrome mouse model.

Authors:  Nobuhiro Kurabayashi; Minh Dang Nguyen; Kamon Sanada
Journal:  EMBO Rep       Date:  2015-09-15       Impact factor: 8.807

2.  OLIG2 Drives Abnormal Neurodevelopmental Phenotypes in Human iPSC-Based Organoid and Chimeric Mouse Models of Down Syndrome.

Authors:  Ranjie Xu; Andrew T Brawner; Shenglan Li; Jing-Jing Liu; Hyosung Kim; Haipeng Xue; Zhiping P Pang; Woo-Yang Kim; Ronald P Hart; Ying Liu; Peng Jiang
Journal:  Cell Stem Cell       Date:  2019-05-23       Impact factor: 24.633

Review 3.  Down syndrome and the complexity of genome dosage imbalance.

Authors:  Stylianos E Antonarakis
Journal:  Nat Rev Genet       Date:  2016-12-28       Impact factor: 53.242

4.  Challenges and Opportunities for Translation of Therapies to Improve Cognition in Down Syndrome.

Authors:  Sarah E Lee; Monica Duran-Martinez; Sabina Khantsis; Diana W Bianchi; Faycal Guedj
Journal:  Trends Mol Med       Date:  2019-11-07       Impact factor: 11.951

5.  Co-expression network analysis of Down's syndrome based on microarray data.

Authors:  Jianping Zhao; Zhengguo Zhang; Shumin Ren; Yanan Zong; Xiangdong Kong
Journal:  Exp Ther Med       Date:  2016-06-17       Impact factor: 2.447

6.  Molecular mechanisms regulating impaired neurogenesis of fragile X syndrome human embryonic stem cells.

Authors:  Michael Telias; Yoav Mayshar; Ami Amit; Dalit Ben-Yosef
Journal:  Stem Cells Dev       Date:  2015-10-15       Impact factor: 3.272

Review 7.  Concise review: new paradigms for Down syndrome research using induced pluripotent stem cells: tackling complex human genetic disease.

Authors:  James A Briggs; Elizabeth A Mason; Dmitry A Ovchinnikov; Christine A Wells; Ernst J Wolvetang
Journal:  Stem Cells Transl Med       Date:  2013-02-14       Impact factor: 6.940

8.  Advancing Knowledge of Down Syndrome Brain Development and Function With Human Stem Cells.

Authors:  Anita Bhattacharyya
Journal:  Am J Intellect Dev Disabil       Date:  2020-03

9.  Generation of kidney organoids from human pluripotent stem cells.

Authors:  Minoru Takasato; Pei X Er; Han S Chiu; Melissa H Little
Journal:  Nat Protoc       Date:  2016-08-18       Impact factor: 13.491

10.  Deficits in human trisomy 21 iPSCs and neurons.

Authors:  Jason P Weick; Dustie L Held; George F Bonadurer; Matthew E Doers; Yan Liu; Chelsie Maguire; Aaron Clark; Joshua A Knackert; Katharine Molinarolo; Michael Musser; Lin Yao; Yingnan Yin; Jianfeng Lu; Xiaoqing Zhang; Su-Chun Zhang; Anita Bhattacharyya
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-28       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.